Retatrutide: what the trials measured
Body weight, blood sugar and liver fat in the published trials, arm by arm, with what is still unknown.
6 min read · 2026-11-17
Body weight, blood sugar and liver fat in the published trials, arm by arm, with what is still unknown.
6 min read · 2026-11-17
Every number here is an average across a group of screened and monitored trial participants. An average is not a forecast for one person, and an amount a protocol assigned is a fact about that study, not guidance for anyone.
The phase 2 obesity trial enrolled 338 adults with a BMI of 30 or higher, or 27 to under 30 with a weight-related condition. They received a once-weekly injection of 1 mg, 4 mg, 8 mg or 12 mg, or placebo, for 48 weeks 1.
At 48 weeks the mean change in body weight was -24.2% in the 12 mg group against -2.1% on placebo. The effect grew with the amount assigned: -8.7% on 1 mg, -17.1% on 4 mg and -22.8% on 8 mg 1.
What the trials measured
Each bar is one arm of a published trial: the mean change in the group assigned that amount. Pick an outcome.
Change in body weight at 48 weeks
| Arm | Mean change |
|---|---|
| Placebo (comparator) | -2.1% |
| 1 mg | -8.7% |
| 4 mg | -17.1% |
| 8 mg | -22.8% |
| 12 mg | -24.2% |
Least-squares mean percentage change from baseline in the phase 2 obesity trial, 338 adults. The 4 mg and 8 mg figures pool two arms that differed only in starting dose. [1]
Pink bars are comparator arms. Results of a trial are averages across a monitored group, not a forecast for a person.
The phase 2 trial in type 2 diabetes enrolled 281 adults. At 24 weeks HbA1c had fallen by 2.02 percentage points on 12 mg, against 0.01 on placebo and 1.41 on dulaglutide 1.5 mg, which the trial used as a comparator. Body weight was down 16.94% at 36 weeks 2.
The phase 3 trial TRANSCEND-T2D-1 enrolled 537 adults whose type 2 diabetes was not controlled by diet and exercise. At 40 weeks HbA1c had fallen by 1.94 points and body weight by 15.3% on 12 mg, against 0.81 points and 2.6% on placebo 4.
A substudy followed 98 participants of the obesity trial who had liver fat of 10% or more on MRI. At 24 weeks the mean relative change in liver fat was -82.4% on 12 mg against +0.3% on placebo, and 86% of the 12 mg group reached normal liver fat 3.
The longest published trial ran 48 weeks, so nothing published describes years of use 1. A trial in people with chronic kidney disease, TRANSCEND-CKD, has published its design and baseline but no results yet 9. A head-to-head trial against tirzepatide is registered and has not reported 12.
A 2025 systematic review pooled four placebo-controlled trials 7. Pooling adds precision. It does not add time: the pooled trials are the same short ones.
Phase 1b: Multiple ascending dose 5
72 people, 12 weeks
Once-weekly subcutaneous injection in five ascending cohorts, the highest stepping 3, 6, 9 then 12 mg; placebo and dulaglutide 1.5 mg as comparators
Half-life approximately 6 days; placebo-adjusted HbA1c down 1.2 to 1.6 points in the three highest groups; placebo-adjusted weight reduction up to 8.96 kg
Phase 2: Obesity 1
338 people, 48 weeks
Once-weekly subcutaneous 1 mg, 4 mg, 8 mg or 12 mg, or placebo; the 4 mg and 8 mg arms started at 2 mg or 4 mg
Body weight -24.2% on 12 mg against -2.1% on placebo at 48 weeks
Phase 2: Type 2 diabetes 2
281 people, 36 weeks
Once-weekly 0.5 mg, 4 mg, 8 mg or 12 mg, placebo, or dulaglutide 1.5 mg
HbA1c -2.02 points on 12 mg at 24 weeks against -0.01 on placebo and -1.41 on dulaglutide; body weight down 16.94% at 36 weeks
Phase 2a: MASLD substudy 3
98 people, 48 weeks
Once-weekly 1 mg, 4 mg, 8 mg or 12 mg, or placebo
Liver fat -82.4% on 12 mg against +0.3% on placebo at 24 weeks; 86% reached normal liver fat
Phase 3: TRANSCEND-T2D-1 4
537 people, 40 weeks
Once-weekly 4 mg, 9 mg or 12 mg, or placebo
HbA1c -1.94 points and body weight -15.3% on 12 mg, against -0.81 points and -2.6% on placebo
Phase 2b: TRANSCEND-CKD 9
146 people, 24 weeks
Once-weekly at the maximum tolerated dose up to 12 mg, or placebo
Design and baseline published; no results yet
The numbers are those of the Retatrutide page, where every source is listed.